BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel. Show more

Location: 22 Einstein Street, Ness Ziona, 7414003, Israel | Website: https://www.biomx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

11.23M

52 Wk Range

$0.34 - $3.58

Previous Close

$0.43

Open

$0.38

Volume

2,253,879

Day Range

$0.36 - $0.42

Enterprise Value

19.6M

Cash

20.12M

Avg Qtr Burn

-8.584M

Insider Ownership

19.08%

Institutional Own.

47.70%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.